Case-Based Learning on Progressive Executive Dysfunction With Mixed Cortical and Subcortical Features

Abstract

Progressive executive dysfunction with mixed cortical and subcortical features represents a complex clinical entity with multifaceted etiologies and significant diagnostic and management challenges. This review synthesizes current knowledge derived from recent research, expert consensus, and clinical guidelines. By leveraging a case-based approach, we examine epidemiology, pathophysiological mechanisms, risk factors, clinical manifestations, diagnostic strategies, therapeutic interventions, and emerging advances. Emphasis is placed on the integration of mechanistic insights and practical considerations for healthcare professionals managing these patients in diverse clinical settings.

Introduction

Executive dysfunction encompasses a spectrum of cognitive deficits involving planning, organizing, initiation, mental flexibility, and abstract reasoning. Progressive forms with mixed cortical and subcortical features commonly arise from neurodegenerative, vascular, or inflammatory processes, impacting both gray and white matter networks. Clinicians face considerable complexity in distinguishing etiologies, predicting progression, and individualizing treatment. The case-based learning model provides a practical framework for understanding nuanced presentations and optimizing patient care.

Epidemiology / Disease Burden

The prevalence of progressive executive dysfunction increases with age and is particularly prominent in populations at risk for dementia, cerebrovascular disease, and movement disorders. Recent studies estimate that up to 40% of patients with mild cognitive impairment (MCI) exhibit significant executive dysfunction, with mixed cortical-subcortical features observed in roughly 15-20% of these cases. The societal and caregiver burden is substantial, given the profound impact on functional independence and quality of life. Moreover, under-recognition of these presentations may contribute to delayed diagnosis and suboptimal care.

Pathophysiology

Mixed cortical and subcortical executive dysfunction arises from disruption of both cortical association areas (notably prefrontal cortex) and subcortical circuits, including the striatum, thalamus, and white matter tracts. Mechanistically, this can result from neurodegenerative processes such as Alzheimer’s disease (AD) with atypical presentations, frontotemporal lobar degeneration (FTLD), or vascular cognitive impairment (VCI) involving small-vessel ischemic changes. Inflammatory, autoimmune, and infectious etiologies may also produce mixed patterns via demyelination or direct neuronal injury. Neuroimaging studies highlight the critical role of fronto-striatal and fronto-parietal network integrity in executive function, while CSF and biomarker analyses increasingly facilitate mechanistic differentiation.

Risk Factors

Major risk factors include advanced age, hypertension, diabetes mellitus, hyperlipidemia, and prior history of cerebrovascular events. Genetic predispositions such as mutations in MAPT or GRN genes (linked to FTLD) and APOE ε4 allele (linked to AD) further increase susceptibility. Lifestyle contributors—physical inactivity, chronic stress, and poor cardiovascular health—are also implicated. Additionally, exposure to neurotoxins, chronic inflammatory states, and traumatic brain injury may predispose individuals to mixed pathology.

Clinical Features

Patients typically present with insidious onset of impaired planning, organization, and goal-directed behavior, often accompanied by cognitive slowing, reduced mental flexibility, and impaired working memory. Behavioral changes such as apathy, disinhibition, or impulsivity may occur, reflecting frontal lobe involvement. Subcortical features include psychomotor slowing, gait disturbances, and urinary incontinence in advanced cases, suggestive of widespread network involvement. Fluctuating attention and subtle language deficits may also be observed, especially where cortical pathology predominates.

Diagnosis

Diagnosis requires a comprehensive clinical assessment, detailed neuropsychological testing focusing on executive domains, and structured informant interviews. MRI is the preferred neuroimaging modality, with attention to patterns of cortical atrophy, white matter hyperintensities, and strategic infarcts. Advanced imaging such as FDG-PET or amyloid/tau PET can clarify underlying pathology in select cases. CSF biomarkers (Aβ42, total tau, phosphorylated tau) and blood-based assays are increasingly utilized for differential diagnosis. Secondary causes including metabolic, infectious, or autoimmune processes should be excluded through targeted laboratory testing.

Treatment & Management

Management is multidisciplinary, encompassing pharmacologic and non-pharmacologic strategies. Cholinesterase inhibitors and memantine may benefit select patients with AD-related pathology, while SSRIs and antipsychotics are reserved for behavioral symptoms. Optimization of vascular risk factors is critical in VCI. Cognitive rehabilitation, occupational therapy, and structured exercise programs have demonstrated efficacy in improving executive function and daily living skills. Family education and caregiver support are essential to maintain patient autonomy and reduce caregiver burden. Periodic reassessment and adjustment of interventions are recommended to address evolving needs.

Recent Advances / Emerging Therapies

Recent advances include the development of monoclonal antibodies targeting amyloid and tau pathology, with promising results in early-phase trials. Novel agents modulating neuroinflammation, synaptic plasticity, and mitochondrial function are under investigation. Digital cognitive training platforms and individualized rehabilitation protocols are gaining traction, leveraging artificial intelligence for tailored interventions. Biomarker-driven stratification is increasingly enabling personalized treatment approaches, while remote monitoring technologies facilitate longitudinal assessment and early detection of clinical deterioration.

Guideline Recommendations

Current clinical guidelines, such as those from the American Academy of Neurology and European Federation of Neurological Societies, advocate for a systematic approach integrating clinical, neuropsychological, and biomarker data. Early identification and management of modifiable risk factors are emphasized. Multidisciplinary collaboration and patient-centered care planning are core recommendations. Guidelines also highlight the need for ongoing research into pathophysiology, diagnostic tools, and therapeutics, given the heterogeneity of presentations and evolving landscape of disease-modifying therapies.

Conclusion

Progressive executive dysfunction with mixed cortical and subcortical features presents a diagnostic and therapeutic challenge in clinical practice. Recent advances in biomarker discovery, neuroimaging, and emerging therapeutics hold promise for enhanced diagnosis and individualized care. A comprehensive, multidisciplinary approach guided by current evidence and evolving guidelines remains essential for optimizing outcomes in affected patients. Continued research and education are vital to address unmet needs and improve quality of life for patients and caregivers alike.